Aliases & Classifications for Neuropathy

MalaCards integrated aliases for Neuropathy:

Name: Neuropathy 12 15 39 17 71
Peripheral Neuropathy 12 71
Peripheral Neuropathies 15

Classifications:



External Ids:

Disease Ontology 12 DOID:870
NCIt 49 C4731
SNOMED-CT 67 386033004
ICD10 32 G62.9
UMLS 71 C0031117 C0442874

Summaries for Neuropathy

Disease Ontology : 12 A nervous system disease that is located in nerves or nerve cells.

MalaCards based summary : Neuropathy, also known as peripheral neuropathy, is related to neuropathy, hereditary, with liability to pressure palsies and neuropathy, hereditary sensory and autonomic, type iia, and has symptoms including seizures, tremor and back pain. An important gene associated with Neuropathy is DLX6-AS1 (DLX6 Antisense RNA 1), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Aztreonam and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include nerves, breast and testes, and related phenotypes are behavior/neurological and cellular

Related Diseases for Neuropathy

Diseases in the Neuropathy family:

Autoimmune Neuropathy Hereditary Neuropathies

Diseases related to Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2735)
# Related Disease Score Top Affiliating Genes
1 neuropathy, hereditary, with liability to pressure palsies 35.2 SPTLC2 PMP22 MPZ MFN2 GJB1 GDAP1
2 neuropathy, hereditary sensory and autonomic, type iia 35.1 WNK1 SPTLC2 SPTLC1 SLC12A6 NGF KIF1A
3 neuropathy, hereditary sensory and autonomic, type v 35.1 WNK1 SPTLC1 NGF KIF1A
4 hypertrophic neuropathy of dejerine-sottas 35.0 PMP22 MPZ MFN2 GJB1 GDAP1
5 neuropathy, congenital hypomyelinating, 1, autosomal recessive 35.0 SPTLC2 SLC12A6 PMP22 MPZ MFN2 GJB1
6 neuropathy, hereditary sensory, type ie 35.0 SPTLC2 SPTLC1 DNMT1
7 hereditary sensory neuropathy 35.0 WNK1 SPTLC2 SPTLC1 NGF MPZ KIF1A
8 hereditary sensory and autonomic neuropathy type 1 35.0 SPTLC2 SPTLC1 DNMT1
9 hereditary motor and sensory neuropathy, type iic 34.9 MPZ MFN2 GJB1 GDAP1
10 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 34.9 SPTLC2 SPTLC1
11 diabetic neuropathy 34.9 PMP22 NGF MPZ
12 neuropathy, hereditary sensory and autonomic, type ia 34.9 WNK1 SPTLC2 SPTLC1
13 hereditary neuropathies 34.9 PMP22 MPZ MFN2 GJB1
14 deafness, x-linked 5, with peripheral neuropathy 34.8 DIAPH3 AIFM1
15 autonomic neuropathy 34.8 WNK1 SPTLC2 SPTLC1 SCN11A NGF KIF1A
16 sensory peripheral neuropathy 34.8 SPTLC1 SLC12A6 POLG PMP22 NGF MPZ
17 neuropathy, hereditary sensory and autonomic, type ic 34.8 SPTLC2 SPTLC1
18 agenesis of the corpus callosum with peripheral neuropathy 34.7 WNK1 SLC12A6
19 motor peripheral neuropathy 34.6 SLC12A6 POLG PMP22 MFN2 KIF1A GJB1
20 autoimmune peripheral neuropathy 34.5 MPZ GJB1
21 charcot-marie-tooth disease, x-linked dominant, 1 34.5 SPTLC1 PMP22 MPZ MFN2 GJB1 GDAP1
22 charcot-marie-tooth disease, axonal, type 2e 34.5 SPTLC1 SLC12A6 PMP22 NGF MPZ MFN2
23 neuropathy, hereditary sensory and autonomic, type iib 34.4 WNK1 KIF1A
24 charcot-marie-tooth disease, demyelinating, type 1b 34.4 PMP22 MPZ MFN2 GJB1 GDAP1
25 charcot-marie-tooth disease, demyelinating, type 1a 34.4 PMP22 MPZ MFN2 GJB1 GDAP1
26 charcot-marie-tooth disease, axonal, type 2b 34.4 SPTLC1 MPZ GJB1 GDAP1
27 charcot-marie-tooth disease, type 4d 34.4 MPZ GJB1 GDAP1
28 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 34.4 MPZ GJB1
29 charcot-marie-tooth disease, demyelinating, type 1c 34.3 PMP22 MPZ GJB1 GDAP1
30 axonal neuropathy 34.3 POLG PMP22 MFN2 GDAP1 GAN AIFM1
31 peripheral nervous system disease 34.3 SPTLC1 SLC12A6 SCN11A POLG PMP22 NGF
32 charcot-marie-tooth disease, axonal, type 2a1 34.3 MPZ MFN2 GDAP1
33 charcot-marie-tooth disease, demyelinating, type 1d 34.3 PMP22 MPZ GJB1 GDAP1
34 charcot-marie-tooth disease/hereditary motor and sensory neuropathy 34.3 SPTLC2 SPTLC1 SLC12A6 PMP22 MPZ MFN2
35 asymmetric motor neuropathy 34.3 PMP22 MFN2 GAN
36 charcot-marie-tooth disease and deafness 34.3 SPTLC2 SPTLC1 PMP22 MPZ MFN2 KIF1A
37 charcot-marie-tooth disease, type 4a 34.2 MPZ MFN2 GJB1 GDAP1
38 optic nerve disease 34.2 POLG NGF MT-ND4 MFN2 GDAP1
39 charcot-marie-tooth disease, demyelinating, type 1f 34.2 MPZ GJB1 GDAP1
40 charcot-marie-tooth disease, axonal, type 2t 34.2 SLC12A6 GDAP1 GAN
41 charcot-marie-tooth disease, dominant intermediate b 34.2 MPZ GJB1 GDAP1
42 charcot-marie-tooth disease, type 4c 34.2 MPZ GJB1 GDAP1
43 charcot-marie-tooth disease, axonal, type 2f 34.2 MPZ MFN2 GJB1 GDAP1
44 charcot-marie-tooth disease, type 4b2 34.2 MPZ GJB1 GDAP1
45 charcot-marie-tooth disease, dominant intermediate a 34.2 MPZ GJB1 GDAP1
46 charcot-marie-tooth disease, axonal, type 2d 34.2 MPZ MFN2 GJB1 GDAP1
47 charcot-marie-tooth disease, axonal, type 2b2 34.2 MPZ MFN2 GDAP1
48 charcot-marie-tooth disease, axonal, type 2i 34.1 MPZ GJB1 GDAP1
49 charcot-marie-tooth disease, axonal, type 2l 34.1 MPZ MFN2 GDAP1
50 charcot-marie-tooth disease, x-linked recessive, 2 34.1 MPZ MFN2 GJB1

Graphical network of the top 20 diseases related to Neuropathy:



Diseases related to Neuropathy

Symptoms & Phenotypes for Neuropathy

UMLS symptoms related to Neuropathy:


seizures, tremor, back pain, headache, syncope, hemiparesis, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, neuralgia, neurologic symptoms, atypical facial pain

MGI Mouse Phenotypes related to Neuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 AIFM1 DNMT1 GAN GDAP1 GJB1 KIF1A
2 cellular MP:0005384 10.22 AIFM1 DIAPH3 DNMT1 GAN GDAP1 GJB1
3 growth/size/body region MP:0005378 10.21 AIFM1 DIAPH3 DNMT1 GAN GJB1 KIF1A
4 homeostasis/metabolism MP:0005376 10.13 AIFM1 DIAPH3 GDAP1 GJB1 GP1BA MFN2
5 integument MP:0010771 10 AIFM1 DIAPH3 DNMT1 GDAP1 KIF1A MPZ
6 mortality/aging MP:0010768 10 AIFM1 DIAPH3 DNMT1 GAN GJB1 KIF1A
7 muscle MP:0005369 9.56 AIFM1 GAN MFN2 NGF PMP22 POLG
8 nervous system MP:0003631 9.5 AIFM1 DNMT1 GAN GDAP1 GJB1 KIF1A

Drugs & Therapeutics for Neuropathy

Drugs for Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 792)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
6
Allopurinol Approved Phase 4 315-30-0 2094
7
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
8
Dinoprostone Approved Phase 4 363-24-6 5280360
9
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
10
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
15
Zidovudine Approved Phase 4 30516-87-1 35370
16
Lopinavir Approved Phase 4 192725-17-0 92727
17
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
18
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
19
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
20
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
21
Liraglutide Approved Phase 4 204656-20-2 44147092
22
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
25
Levodopa Approved Phase 4 59-92-7 6047
26
Carbidopa Approved Phase 4 28860-95-9 34359
27
Glucagon Approved Phase 4 16941-32-5
28
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
29
Nortriptyline Approved Phase 4 72-69-5 4543
30
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
31
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
32
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
33
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
34
Travoprost Approved Phase 4 157283-68-6 5282226
35
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
36
Glimepiride Approved Phase 4 93479-97-1 3476
37
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
38
Propranolol Approved, Investigational Phase 4 525-66-6 4946
39
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
40
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
41
Methimazole Approved Phase 4 60-56-0 1349907
42
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
43
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
44
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
45
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
46
Acetaminophen Approved Phase 4 103-90-2 1983
47
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
48
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
49
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
50
Morphine Approved, Investigational Phase 4 57-27-2 5288826

Interventional clinical trials:

(show top 50) (show all 2276)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
2 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3 Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY Unknown status NCT00235222 Phase 4 stavudine
4 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
5 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
6 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
7 A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
8 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
9 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
10 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
11 The Effects of Omega-3 Fatty Acids on Chemotherapy-induced Neuropathy and Inflammation in Patients With Breast Cancer Unknown status NCT01049295 Phase 4
12 Botox on Vulvar Vestibulitis Unknown status NCT00119886 Phase 4 Botulinum toxin
13 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Unknown status NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
14 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Unknown status NCT02535000 Phase 4 Duloxetine;Placebo
15 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
16 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
17 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
18 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
19 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
20 Effects of Pregabalin on Mechanical Hyperalgesia - EPOM Unknown status NCT00310583 Phase 4 Pregabalin
21 A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
22 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
23 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
24 Absorption and Utilization of a Mixed Meal in Type 1 Diabetes: Creation of a Biological and In Silico Biobank for the Optimization of Artificial Pancreas Systems. A Pilot Study. Unknown status NCT01800734 Phase 4
25 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Unknown status NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
26 Multicentre Randomised Controled Trial Comparing the Effect of a New Self-gripping Lightweight Polyester Mesh and a Normal Sutured Lightweight Polyester Mesh on the Incidence of Chronic Inguinodynia in Lichtenstein Hernioplasty. Unknown status NCT01830452 Phase 4
27 A Prospective Single Blind Randomised Controlled Study to Compare the Outcomes of Patients With Diabetes and Clinically Non-infected Neuro-ischaemic and Neuropathic Foot Ulcers Treated With and Without Oral Antibiotics. Unknown status NCT01418456 Phase 4 antibiotics
28 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
29 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
30 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
31 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
32 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
33 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
34 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
35 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
36 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
37 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
38 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
39 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
40 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
41 A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
42 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
43 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
44 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
45 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
46 L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients Completed NCT00902616 Phase 4
47 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
48 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
49 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
50 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch

Search NIH Clinical Center for Neuropathy

Genetic Tests for Neuropathy

Anatomical Context for Neuropathy

The Foundational Model of Anatomy Ontology organs/tissues related to Neuropathy:

19
Nerves

MalaCards organs/tissues related to Neuropathy:

40
Breast, Testes, Skin, Lung, Heart, Brain, Spinal Cord

Publications for Neuropathy

Articles related to Neuropathy:

(show top 50) (show all 40000)
# Title Authors PMID Year
1
Histologic evaluation of femoral nerve demyelinating and axonal neuropathy in Wistar rats due to alendronate intake: a randomised study. 61
32099834 2020
2
The effect of rat nerve growth factor combined with vitamin B on peripheral neuropathy in multiple myeloma patients. 61
32567522 2020
3
Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. 61
32464241 2020
4
mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment. 61
32512114 2020
5
Insights into platinum-induced peripheral neuropathy-current perspective. 61
32209761 2020
6
Beneficial effects of ferulic acid alone and in combination with insulin in streptozotocin induced diabetic neuropathy in Sprague Dawley rats. 61
32473246 2020
7
The isoform-specific functions of the c-Jun N-terminal kinase (JNK) in a mouse model of antiretroviral-induced painful peripheral neuropathy. 61
32416188 2020
8
Metformin protects from oxaliplatin induced peripheral neuropathy in rats. 61
32490289 2020
9
Escin alleviates peripheral neuropathy in streptozotocin induced diabetes in rats. 61
32407839 2020
10
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. 61
32416186 2020
11
It is not your eyes. 61
31009615 2020
12
A recessive Trim2 mutation causes an axonal neuropathy in mice. 61
32205255 2020
13
Radiation optic neuropathy and stroke suspicion. 61
32571566 2020
14
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. 61
32170867 2020
15
A Randomized Controlled Trial to Assess the Effectiveness of Muscle Strengthening and Balancing Exercises on Chemotherapy-Induced Peripheral Neuropathic Pain and Quality of Life Among Cancer Patients. 61
30888982 2020
16
Long lasting trigeminal neuropathy, limbic encephalitis and abdominal ganglionitis without primary cancer: An atypical case of Hu-antibody syndrome. 61
32388246 2020
17
Treatment induced neuropathy of diabetes. 61
32247944 2020
18
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. 61
32502876 2020
19
Central nervous system complications associated with immune checkpoint inhibitors. 61
32312871 2020
20
Optic nerve atrophy and whole and regional brain atrophy in Leber's hereditary optic neuropathy with multiple sclerosis-like disease with m.11778G>A mutation. 61
32387972 2020
21
Molecular analysis and clinical diversity of distal hereditary motor neuropathy. 61
32298515 2020
22
Linear mixed-effects models for the analysis of high-density electromyography with application to diabetic peripheral neuropathy. 61
32447652 2020
23
Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level. 61
32559841 2020
24
IFN-γ/mTORC1 decreased Rab11 in Schwann cells of diabetic peripheral neuropathy, inhibiting cell proliferation via GLUT1 downregulation. 61
31970777 2020
25
Clinical characteristics of fibroblast growth factor receptor 3 antibody-related polyneuropathy: a retrospective study. 61
32068339 2020
26
Agomelatine potentiates anti-nociceptive effects of morphine in a mice model for diabetic neuropathy: involvement of NMDA receptor subtype NR1 within the raphe nucleus and periaqueductal grey. 61
32336224 2020
27
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. 61
32284437 2020
28
ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy. 61
32219868 2020
29
Sarcoidosis with cutaneous perineural granulomas and neurological manifestations: A potential mimicker of leprosy. 61
32022940 2020
30
Vestibular dysfunction in patients with auditory neuropathy detected by vestibular evoked myogenic potentials. 61
32089450 2020
31
Is ultrasound better than electrodiagnosis for the diagnosis of compressive neuropathy? 61
32362459 2020
32
Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients. 61
32124075 2020
33
The LFA-1 antagonist BIRT377 reverses neuropathic pain in prenatal alcohol-exposed female rats via actions on peripheral and central neuroimmune function in discrete pain-relevant tissue regions. 61
31918004 2020
34
Topical Delivery of Muscarinic Receptor Antagonists Prevents and Reverses Peripheral Neuropathy in Female Diabetic Mice. 61
32327528 2020
35
Nutritional neuropathies. 61
31837157 2020
36
Hypertrophic Interstitial Neuropathy of the Trigeminal Nerve: Case Report and Literature Review. 61
31620786 2020
37
Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. 61
32315091 2020
38
cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons. 61
32087251 2020
39
Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. 61
32352155 2020
40
Electrophysiology and ultrasonography in the diagnosis of ulnar neuropathy at the elbow. 61
32345517 2020
41
Reply to "Electrophysiology and ultrasonography in the diagnosis of ulnar neuropathy at the elbow". 61
32349940 2020
42
Treatment of diabetic peripheral neuropathy: a review. 61
32067247 2020
43
Getting the balance right in auditory neuropathy. 61
32327271 2020
44
Continuous subcutaneous insulin infusion and neuropathy in older people. 61
32276296 2020
45
Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy. 61
32487720 2020
46
Recurrent alternating ophthalmoplegia with ipsilateral headache: unusual but possible manifestation of recurrent painful ophthalmoplegic neuropathy. 61
32504277 2020
47
The ataxic neuropathies. 61
32556571 2020
48
Cerebellar ataxia, neuropathy, hearing loss, and intellectual disability due to AIFM1 mutation. 61
32337346 2020
49
Pupil fields in patients with Leber hereditary optic neuropathy. 61
32518975 2020
50
Recurrent Bilateral Myelin Oligodendrocyte Glycoprotein Antibody Optic Neuritis in a Leber Hereditary Optic Neuropathy Carrier. 61
31842145 2020

Variations for Neuropathy

Copy number variations for Neuropathy from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107544 17 15900000 22100000 Microdeletion Neuropathy
2 107574 17 16000000 22200000 Copy number Neuropathy
3 216423 6 92100000 98700000 Microdeletion EPHA7 Neuropathy

Expression for Neuropathy

Search GEO for disease gene expression data for Neuropathy.

Pathways for Neuropathy

Pathways related to Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 PMP22 MPZ GJB1

GO Terms for Neuropathy

Cellular components related to Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.83 WNK1 SPTLC2 SPTLC1 SLC12A6 SCN11A POLG
2 serine C-palmitoyltransferase complex GO:0017059 8.62 SPTLC2 SPTLC1

Biological processes related to Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial fusion GO:0008053 9.32 MFN2 GDAP1
2 sphingosine biosynthetic process GO:0046512 9.26 SPTLC2 SPTLC1
3 sphingomyelin biosynthetic process GO:0006686 9.16 SPTLC2 SPTLC1
4 positive regulation of lipophagy GO:1904504 8.96 SPTLC2 SPTLC1
5 sphinganine biosynthetic process GO:0046511 8.62 SPTLC2 SPTLC1

Molecular functions related to Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine C-palmitoyltransferase activity GO:0004758 8.62 SPTLC2 SPTLC1

Sources for Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
14